Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 662.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,277 shares of the medical equipment provider's stock after buying an additional 8,929 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund's holdings in Intuitive Surgical were worth $5,090,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Onefund LLC lifted its position in shares of Intuitive Surgical by 1.9% in the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock valued at $494,000 after acquiring an additional 18 shares in the last quarter. AlphaCore Capital LLC lifted its position in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after acquiring an additional 18 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Intuitive Surgical by 2.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after acquiring an additional 19 shares in the last quarter. Accredited Investors Inc. lifted its position in shares of Intuitive Surgical by 1.9% in the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after acquiring an additional 19 shares in the last quarter. Finally, Second Line Capital LLC lifted its position in shares of Intuitive Surgical by 3.4% in the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after acquiring an additional 19 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president now directly owns 907 shares of the company's stock, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gary Loeb sold 1,700 shares of Intuitive Surgical stock in a transaction on Friday, April 25th. The shares were sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the sale, the executive vice president now directly owns 2,245 shares of the company's stock, valued at $1,152,089.10. The trade was a 43.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock valued at $2,611,577 over the last quarter. 0.70% of the stock is owned by insiders.

Intuitive Surgical Trading Up 1.1%

ISRG stock traded up $5.73 during midday trading on Monday, hitting $515.09. 1,217,351 shares of the company's stock were exchanged, compared to its average volume of 1,675,816. The business has a 50-day simple moving average of $528.03 and a two-hundred day simple moving average of $537.31. The stock has a market capitalization of $184.62 billion, a PE ratio of 75.53, a P/E/G ratio of 5.40 and a beta of 1.67. Intuitive Surgical, Inc. has a 1-year low of $413.82 and a 1-year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same quarter last year, the firm earned $1.50 earnings per share. As a group, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ISRG shares. Piper Sandler decreased their target price on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Royal Bank Of Canada decreased their target price on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Citigroup restated a "buy" rating and issued a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Truist Financial reduced their price objective on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Finally, Barclays reduced their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $588.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.